<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04672447</url>
  </required_header>
  <id_info>
    <org_study_id>20-0152</org_study_id>
    <nct_id>NCT04672447</nct_id>
  </id_info>
  <brief_title>Effect of 4 Weeks of Citrulline and Glutathione Supplementation on Arterial Function</brief_title>
  <official_title>Effects of 4 Weeks Supplementation With L-Citrulline and Glutathione on Arterial Function and Cardiovascular Responses in Postmenopausal Healthy Women: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Tech University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyowa Hakko Bio Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Texas Tech University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examining the effects of 4 weeks of Citrulline alone or in combination with glutathione on&#xD;
      the arterial function of postmenopausal women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      L-Citrulline is a non-protein amino acid and an efficient precursor of L-arginine, the&#xD;
      substrate for endothelial nitric oxide synthesis. Glutathione is a tripeptide with&#xD;
      antioxidant effects. Postmenopausal women will ingest 6g/d of L-Citrulline or 2g of&#xD;
      L-Citrulline plus 200mg/d of glutathione or placebo (maltodextrin) for 4 weeks with vascular&#xD;
      function testing prior to and after the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator)</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomized, placebo-controlled, double-blind, parallel-groups study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in endothelial function</measure>
    <time_frame>4 weeks</time_frame>
    <description>Endothelial function will be measured before and after the intervention using brachial artery flow mediated dilation at rest, blood flow measured in the brachial artery during handgrip exercise, and blood flow in the common femoral artery during passive leg movement. All measurements performed using doppler ultrasound.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in arterial stiffness</measure>
    <time_frame>4 weeks</time_frame>
    <description>Arterial stiffness will be assessed through measurement of pulse-wave velocity of the carotid-femoral, carotid radial, carotid-ankle and femoral ankle arterial segments before and after the 4 week interventions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure control during the cold pressor test</measure>
    <time_frame>4 weeks</time_frame>
    <description>Blood pressure will be measured during the cold pressor test before and after the 4 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>L-Arginine bioavailability</measure>
    <time_frame>4 weeks</time_frame>
    <description>Plasma levels of arginine will be measured before and after the 4 week intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiovascular hemodynamics using pulse wave analysis during the cold pressor test</measure>
    <time_frame>4 weeks</time_frame>
    <description>arterial tonometry will be measured during the cold pressor test before and after the 4 week intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body composition</measure>
    <time_frame>4 weeks</time_frame>
    <description>We will determine whether L-citrulline + glutathione changes body composition more than L-citrulline or placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength</measure>
    <time_frame>4 weeks</time_frame>
    <description>Leg Extension strength will be measured before and after the 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L-Citrulline levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>Plasma levels of L-Citrulline will be measured before and after the 4 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glutathione peroxidase levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>Blood levels of glutathione peroxidase will be measured before and after the 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Malondialdehyde</measure>
    <time_frame>4 weeks</time_frame>
    <description>blood levels of malondialdehyde will be measured before and after the 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L-Ornithine levels</measure>
    <time_frame>4 weeks</time_frame>
    <description>plasma levels of L-ornithine will be measured before and after the 4 weeks</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Menopause</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>L-Citrulline + Glutathione</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citrulline: 2 grams/day, Glutathione: 200mg/day for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>L-Citrulline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Citrulline: 6 grams/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin: 6 grams/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Citrulline</intervention_name>
    <description>Four weeks of oral L-Citrulline (2 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.</description>
    <arm_group_label>L-Citrulline + Glutathione</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-Citrulline</intervention_name>
    <description>Four weeks of oral L-Citrulline (6 grams/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.</description>
    <arm_group_label>L-Citrulline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Four weeks of oral placebo (6 grams/day maltodextrin) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glutathione</intervention_name>
    <description>Four weeks of Glutathione (200mg/day) supplementation. Supplementation will be ingested daily, half of the doses in the morning and half at night.</description>
    <arm_group_label>L-Citrulline + Glutathione</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Generally healthy, postmenopausal women (defined as the absence of menstruation for at&#xD;
             least 1 year).&#xD;
&#xD;
          2. Between the ages of 50-79 years.&#xD;
&#xD;
          3. Body mass index of 18.5 - 34.9 kg/m2.&#xD;
&#xD;
          4. Brachial systolic blood pressure &lt; 150 mmHg, and diastolic blood pressure &lt; 90 mmHg.&#xD;
&#xD;
          5. Sedentary (defined as &lt; 120 min/week of exercise).&#xD;
&#xD;
          6. Be willing and able to comfortably abstain from any of food supplements for the period&#xD;
             of time beginning 1 month prior to the study to the time of the termination of the&#xD;
             study.&#xD;
&#xD;
          7. Not participating as a subject in another study for at least 2 months prior to the&#xD;
             study and for the duration of this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current or prior use of tobacco products, e-cigarettes or other inhaled substance.&#xD;
&#xD;
          2. Use of medications and/or any supplements that may affect outcome variables (such as&#xD;
             arginine-containing supplements, nitroglycerin, statin drugs, but not limited to&#xD;
             those.)&#xD;
&#xD;
          3. Taking hormone replacement therapy during the 3 months before the study.&#xD;
&#xD;
          4. More than a moderate intake of alcohol (&gt;7 drink per week).&#xD;
&#xD;
          5. Cardiovascular diseases, diabetes and other metabolic or chronic diseases.&#xD;
&#xD;
          6. Musculoskeletal disorders that will prevent exercise performance.&#xD;
&#xD;
          7. Currently taking more than one vasoactive drug for blood pressure control.&#xD;
&#xD;
               -  Subject having no more than one drug for prevention, which does not affect&#xD;
                  variables, may be included, but will be diagnosed as not having a disease.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arturo Figueroa</last_name>
    <phone>806-834-5587</phone>
    <email>arturo.figueroa@ttu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>TTU Kinesiology and Sport Management Building</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arturo Figueroa, M.D., Ph.D.</last_name>
      <phone>806-834-5587</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endothelial Function</keyword>
  <keyword>Aortic Hemodynamics</keyword>
  <keyword>Pressure Wave Reflection</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

